Futures slip, bank earnings ahead, Powell to speak - what’s moving markets
Veracyte Inc (NASDAQ:VCYT), a $2.56 billion diagnostics company, saw Chief Executive Officer Marc Stapley sell 7,667 shares of common stock on September 4, 2025, for approximately $233,132. The shares were sold at a weighted average price of $30.4073, with individual sales prices ranging from $30.22 to $30.66. The stock currently trades at $32.46, showing a 7% gain since the transaction. According to InvestingPro, analysts maintain a bullish stance with price targets ranging from $28 to $45.
Following the transaction, Stapley directly owns 334,185 shares of Veracyte.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 13, 2024.
In other recent news, Veracyte Inc . reported a significant earnings beat for the second quarter of 2025, with earnings per share reaching $0.44, far exceeding analyst forecasts of $0.11. The company’s revenue also surpassed expectations, coming in at $130.2 million compared to the projected $121.1 million. These results highlight a strong performance driven by momentum in Veracyte’s Decipher and Afirma product lines. William Blair has reiterated its Outperform rating on Veracyte following the strong second-quarter performance, noting that revenue was 8% ahead of consensus estimates. Morgan Stanley, however, has adjusted its price target for Veracyte to $28.00 from $29.00, while maintaining an Underweight rating. In other developments, Veracyte has completed enrollment for its NIGHTINGALE clinical trial, which involves 2,400 patients and aims to assess the utility of the Percepta Nasal Swab test for lung nodule assessment. The trial is being conducted across more than 90 centers in the United States. Participants in the trial will be monitored for up to two years to evaluate the test’s effectiveness in reducing unnecessary procedures for benign nodules.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.